Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors. / Puig-Blasco, Laia; Piotrowski, Krzysztof B; Michaelsen, Signe R; Bager, Nicolai S; Areškevičiūtiė, Aušrinė; Thorseth, Marie-Louise; Sun, Xiao-Feng; Keller, Ulrich Auf dem; Kristensen, Bjarne W; Madsen, Daniel H; Gnosa, Sebastian P; Kveiborg, Marie.

I: International Journal of Cancer, Bind 153, Nr. 12, 2023, s. 2068–2081.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Puig-Blasco, L, Piotrowski, KB, Michaelsen, SR, Bager, NS, Areškevičiūtiė, A, Thorseth, M-L, Sun, X-F, Keller, UAD, Kristensen, BW, Madsen, DH, Gnosa, SP & Kveiborg, M 2023, 'Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors', International Journal of Cancer, bind 153, nr. 12, s. 2068–2081. https://doi.org/10.1002/ijc.34695

APA

Puig-Blasco, L., Piotrowski, K. B., Michaelsen, S. R., Bager, N. S., Areškevičiūtiė, A., Thorseth, M-L., Sun, X-F., Keller, U. A. D., Kristensen, B. W., Madsen, D. H., Gnosa, S. P., & Kveiborg, M. (2023). Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors. International Journal of Cancer, 153(12), 2068–2081. https://doi.org/10.1002/ijc.34695

Vancouver

Puig-Blasco L, Piotrowski KB, Michaelsen SR, Bager NS, Areškevičiūtiė A, Thorseth M-L o.a. Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors. International Journal of Cancer. 2023;153(12):2068–2081. https://doi.org/10.1002/ijc.34695

Author

Puig-Blasco, Laia ; Piotrowski, Krzysztof B ; Michaelsen, Signe R ; Bager, Nicolai S ; Areškevičiūtiė, Aušrinė ; Thorseth, Marie-Louise ; Sun, Xiao-Feng ; Keller, Ulrich Auf dem ; Kristensen, Bjarne W ; Madsen, Daniel H ; Gnosa, Sebastian P ; Kveiborg, Marie. / Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors. I: International Journal of Cancer. 2023 ; Bind 153, Nr. 12. s. 2068–2081.

Bibtex

@article{2dd584f687ba48b893896dd82e7e7946,
title = "Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors",
abstract = "Tumor progression and response to treatment are highly affected by interactions between cancer cells and the tumor microenvironment (TME). Many of the soluble factors and signaling receptors involved in this crosstalk are shed by a disintegrin and metalloproteinases (ADAMs). Upregulation of ADAM15 has been linked to worse survival in cancer patients and a tumor-promoting function both in vitro and in murine cancer models. Although ADAM15 has been involved in cell-cell and cell-extracellular matrix interactions, its role in the crosstalk between cancer cells and the TME in vivo remains unexplored. Therefore, we aimed to understand how ADAM15 regulates the cell composition of the TME and how it affects tumor progression. Here, we showed an upregulation of ADAM15 in tumor tissues from rectal cancer patients. Subcutaneous injection of wildtype and ADAM15-knockout CT26 colon cancer cells in syngeneic mice confirmed the protumorigenic role of ADAM15. Profiling of tumors revealed higher immune cell infiltration and cancer cell apoptosis in the ADAM15-deficient tumors. Specifically, loss of ADAM15 led to a reduced number of granulocytes and higher infiltration of antigen-presenting cells, including dendritic cells and macrophages, as well as more T cells. Using in vitro assays, we confirmed the regulatory effect of ADAM15 on macrophage migration and identified ADAM15-derived CYR61 as a potential molecular mediator of this effect. Based on these findings, we speculate that targeting ADAM15 could increase the infiltration of immune cells in colorectal tumors, which is a prerequisite for effective immunotherapy.",
author = "Laia Puig-Blasco and Piotrowski, {Krzysztof B} and Michaelsen, {Signe R} and Bager, {Nicolai S} and Au{\v s}rinė Are{\v s}kevi{\v c}iūtiė and Marie-Louise Thorseth and Xiao-Feng Sun and Keller, {Ulrich Auf dem} and Kristensen, {Bjarne W} and Madsen, {Daniel H} and Gnosa, {Sebastian P} and Marie Kveiborg",
note = "{\textcopyright} 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.",
year = "2023",
doi = "10.1002/ijc.34695",
language = "English",
volume = "153",
pages = "2068–2081",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley",
number = "12",

}

RIS

TY - JOUR

T1 - Loss of cancer cell-derived ADAM15 alters the tumor microenvironment in colorectal tumors

AU - Puig-Blasco, Laia

AU - Piotrowski, Krzysztof B

AU - Michaelsen, Signe R

AU - Bager, Nicolai S

AU - Areškevičiūtiė, Aušrinė

AU - Thorseth, Marie-Louise

AU - Sun, Xiao-Feng

AU - Keller, Ulrich Auf dem

AU - Kristensen, Bjarne W

AU - Madsen, Daniel H

AU - Gnosa, Sebastian P

AU - Kveiborg, Marie

N1 - © 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

PY - 2023

Y1 - 2023

N2 - Tumor progression and response to treatment are highly affected by interactions between cancer cells and the tumor microenvironment (TME). Many of the soluble factors and signaling receptors involved in this crosstalk are shed by a disintegrin and metalloproteinases (ADAMs). Upregulation of ADAM15 has been linked to worse survival in cancer patients and a tumor-promoting function both in vitro and in murine cancer models. Although ADAM15 has been involved in cell-cell and cell-extracellular matrix interactions, its role in the crosstalk between cancer cells and the TME in vivo remains unexplored. Therefore, we aimed to understand how ADAM15 regulates the cell composition of the TME and how it affects tumor progression. Here, we showed an upregulation of ADAM15 in tumor tissues from rectal cancer patients. Subcutaneous injection of wildtype and ADAM15-knockout CT26 colon cancer cells in syngeneic mice confirmed the protumorigenic role of ADAM15. Profiling of tumors revealed higher immune cell infiltration and cancer cell apoptosis in the ADAM15-deficient tumors. Specifically, loss of ADAM15 led to a reduced number of granulocytes and higher infiltration of antigen-presenting cells, including dendritic cells and macrophages, as well as more T cells. Using in vitro assays, we confirmed the regulatory effect of ADAM15 on macrophage migration and identified ADAM15-derived CYR61 as a potential molecular mediator of this effect. Based on these findings, we speculate that targeting ADAM15 could increase the infiltration of immune cells in colorectal tumors, which is a prerequisite for effective immunotherapy.

AB - Tumor progression and response to treatment are highly affected by interactions between cancer cells and the tumor microenvironment (TME). Many of the soluble factors and signaling receptors involved in this crosstalk are shed by a disintegrin and metalloproteinases (ADAMs). Upregulation of ADAM15 has been linked to worse survival in cancer patients and a tumor-promoting function both in vitro and in murine cancer models. Although ADAM15 has been involved in cell-cell and cell-extracellular matrix interactions, its role in the crosstalk between cancer cells and the TME in vivo remains unexplored. Therefore, we aimed to understand how ADAM15 regulates the cell composition of the TME and how it affects tumor progression. Here, we showed an upregulation of ADAM15 in tumor tissues from rectal cancer patients. Subcutaneous injection of wildtype and ADAM15-knockout CT26 colon cancer cells in syngeneic mice confirmed the protumorigenic role of ADAM15. Profiling of tumors revealed higher immune cell infiltration and cancer cell apoptosis in the ADAM15-deficient tumors. Specifically, loss of ADAM15 led to a reduced number of granulocytes and higher infiltration of antigen-presenting cells, including dendritic cells and macrophages, as well as more T cells. Using in vitro assays, we confirmed the regulatory effect of ADAM15 on macrophage migration and identified ADAM15-derived CYR61 as a potential molecular mediator of this effect. Based on these findings, we speculate that targeting ADAM15 could increase the infiltration of immune cells in colorectal tumors, which is a prerequisite for effective immunotherapy.

U2 - 10.1002/ijc.34695

DO - 10.1002/ijc.34695

M3 - Journal article

C2 - 37602921

VL - 153

SP - 2068

EP - 2081

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -

ID: 363613114